Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6
Main Authors: | Stefanie Felicitas Färber, Alexander Wurzer, Florian Reichart, Roswitha Beck, Horst Kessler, Hans-Jürgen Wester, Johannes Notni |
---|---|
Format: | Article |
Language: | English |
Published: |
American Chemical Society
2018-02-01
|
Series: | ACS Omega |
Online Access: | http://dx.doi.org/10.1021/acsomega.8b00035 |
Similar Items
-
It’s Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals
by: Susanne Kossatz, et al.
Published: (2021-11-01) -
Exploring the Role of RGD-Recognizing Integrins in Cancer
by: Markus Nieberler, et al.
Published: (2017-09-01) -
In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography
by: Johannes Notni, et al.
Published: (2019-09-01) -
There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography
by: Katja Steiger, et al.
Published: (2021-10-01) -
Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3.
by: Neubauer, S, et al.
Published: (2013)